Skip to main content

Sitagliptin

Close up of mixed medications

09-12-2022 | Medications | News

TriMaster data support ‘try before you choose’ for type 2 diabetes medications

Allowing people to try out medications for type 2 diabetes and choose their preferred one is a viable approach in the absence of a clear clinical indication, say the TriMaster investigators.

Arrow on target

29-09-2021 | EASD 2021 | Conference coverage | News

TriMaster supports precision medicine strategy for type 2 diabetes treatment intensification

Findings from the TriMaster trial suggest that stratification of people with type 2 diabetes based on clinical features may help to guide the choice of second- or third-line drug for those who require treatment intensification after metformin.

Treatment algorithm

29-06-2021 | ADA 2021 | Conference coverage | News

​​​​​​​Trial GRADEs effectiveness of four common second-line type 2 diabetes drugs

Findings from the GRADE study, a head-to-head comparison of four commonly used diabetes drugs given together with metformin, suggest that liraglutide and insulin may result in better glycemic control than glimepiride and sitagliptin among people with type 2 diabetes.

08-02-2021 | COVID-19 | News

No need to discontinue DPP-4 inhibitors during hospitalization for COVID-19

Results from the CORONADO study indicate that use of DPP-4 inhibitors does not affect outcomes for people with type 2 diabetes admitted to hospital with COVID-19.

30-09-2020 | COVID-19 | News

Early findings suggest sitagliptin benefits for COVID-19 in diabetes

Findings from a retrospective case–control study suggest that the DPP-4 inhibitor sitagliptin may improve outcomes in people with type 2 diabetes who are hospitalized with COVID-19.

VERIFY trial results

25-10-2019 | Sitagliptin | Highlight | News

Further support for early combination therapy in type 2 diabetes

Adding the DPP-4 inhibitor sitagliptin to first-line metformin therapy may delay the need for exogenous insulin among people with type 2 diabetes, researchers report.

09-06-2019 | Semaglutide | ADA 2019 | News

PIONEER trials test oral semaglutide in moderate renal impairment, flexible dosing

The PIONEER 5 and 7 trials show the efficacy of oral semaglutide in people with moderate renal impairment and the potential for a flexible dosing regimen.

Pills in hand

26-03-2019 | Semaglutide | Highlight | News

PIONEER 3: Oral semaglutide proves worth against sitagliptin

Oral semaglutide offers greater efficacy for glucose control and weight loss when compared with sitagliptin for people with type 2 diabetes, although with more adverse events at the highest dose, show the PIONEER 3 findings.